Nina Hwang
Pediatrics · Orange, CANPI 1427286343
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $70,986 of the $108,028 with a category attached, or 65.7%. It is spread thinly across 30 manufacturers, the largest accounting for just 18.3%. Among pediatrics clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $461.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$20K
- HEMA Biologics, LLC$17K
- Takeda Pharmaceuticals U.S.A., Inc.$15K
- Sanofi-aventis U.S. LLC$12K
- Sanofi US Services Inc.$10K
- Octapharma USA, Inc.$9K
- plus $24K from 24 others
Across 21 payments — averaging $3286.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$31K
- Takeda Pharmaceuticals U.S.A., Inc.$21K
- Bioverativ Therapeutics Inc.$17K
What the payments were for
- Consulting fees$70,98666%
- Speaking & faculty fees$19,34418%
- Travel & lodging$9,6539%
- Food & beverage$7,7077%
- Education$3370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 35 | $19,768 |
| HEMA Biologics, LLC | 27 | $17,404 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $15,046 |
| Sanofi-aventis U.S. LLC | 11 | $12,418 |
| Sanofi US Services Inc. | 1 | $10,385 |
| Octapharma USA, Inc. | 22 | $9,050 |
| Genentech USA, Inc. | 18 | $7,793 |
| Pfizer | 12 | $6,975 |
| Medexus Pharma, Inc. | 2 | $2,619 |
| Shire North American Group Inc | 13 | $1,447 |
| Bioverativ Therapeutics Inc. | 4 | $1,359 |
| CSL Behring | 5 | $1,064 |
| Novo Nordisk | 20 | $655 |
| Biomarin Pharmaceutical Inc. | 8 | $363 |
| Spark Therapeutics, Inc. | 6 | $345 |
| Bayer | 7 | $329 |
| Genentech, Inc. | 7 | $316 |
| Novartis | 3 | $167 |
| Rigel Pharmaceuticals, Inc. | 2 | $137 |
| Vertex | 3 | $80 |
| Kedrion Biopharma, Inc. | 1 | $53 |
| Agios Pharmaceuticals, Inc. | 2 | $49 |
| Global Blood Therapeutics, Inc. | 2 | $38 |
| AstraZeneca | 1 | $31 |
| Chiesi USA, Inc. | 2 | $30 |
| Sobi, Inc | 1 | $23 |
| Bio Products Laboratory USA, Inc. | 1 | $23 |
| Genetix Biotherapeutics Inc | 1 | $22 |
| Aptevo Therapeutics Inc | 1 | $19 |
| Emmaus Medical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$108,028 in reported general payments places this provider in the 95th percentile of 5,539 pediatrics providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 14 | $8,268 |
Paid to pharmacies, not to this prescriber.
Other pediatrics in Orange
- Nancy KuntzOrange$103K
- Raymond WangOrange$30K
- Laurene MascolaLos Angeles$451K
- Tonya ChaffeeSan Francisco$359K
- Anthony PortaleSan Francisco$354K
- David KesslerSan Francisco$335K
- Lawrence SherRolling Hills Estates$297K
- Steven BlackOakland$228K
- Jonathan StroberSan Francisco$164K
- Hasmukh AminBakersfield$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.